{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:42:34Z","timestamp":1709253754455},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"DOI":"10.7759\/cureus.55258","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T18:23:18Z","timestamp":1709230998000},"source":"Crossref","is-referenced-by-count":0,"title":["Anaplastic Lymphoma Kinase (ALK)-Negative Anaplastic Large Cell Non-Hodgkin Lymphoma as a Rare Differential Diagnosis of Lung Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Alondra Esthefan\u00eda","family":"Llamas Dom\u00ednguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio A","family":"Palma Zapata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Denise","family":"Ponce Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Palma Zapata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvia","family":"Jacobo Medrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Cisneros Garza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000249","article-title":"Primary mediastinal nodal and extranodal non-Hodgkin lymphomas: current concepts, historical evolution, and useful diagnostic approach: part 1","volume":"26","author":"Pi\u00f1a-Oviedo S","year":"2019","unstructured":"Pi\u00f1a-Oviedo S, Moran CA. Primary mediastinal nodal and extranodal non-Hodgkin lymphomas: current concepts, historical evolution, and useful diagnostic approach: part 1. Adv Anat Pathol. 2019, 26:346-370. 10.1097\/PAP.0000000000000249","journal-title":"Adv Anat Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019166","article-title":"Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma","volume":"142","author":"Song Z","year":"2023","unstructured":"Song Z, Wu W, Wei W, et al.. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma. Blood. 2023, 142:1297-1311. 10.1182\/blood.2022019166","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V130.SUPPL_1.5129.5129","article-title":"Anaplastic large-cell lymphomas in adults: the cytogenetic and molecular genetic characteristics, treatment results (a single institutional experience)","volume":"130","author":"Castellar ERP","year":"2017","unstructured":"Castellar ERP, Jaffe ES, Said JW, et al.. Anaplastic large-cell lymphomas in adults: the cytogenetic and molecular genetic characteristics, treatment results (a single institutional experience). Blood. 2017, 130:5129. 10.1182\/BLOOD.V130.SUPPL_1.5129.5129","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo E","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, et al.. The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022, 140:1229-1253. 10.1182\/blood.2022015851","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al.. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022, 36:1720-1748. 10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.17023","article-title":"Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects","volume":"57","author":"Tsuyama N","year":"2017","unstructured":"Tsuyama N, Sakamoto K, Sakata S, Dobashi A, Takeuchi K. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop. 2017, 57:120-142. 10.3960\/jslrt.17023","journal-title":"J Clin Exp Hematop"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136978","article-title":"Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010","volume":"65","author":"Hooper C","year":"2010","unstructured":"Hooper C, Lee YC, Maskell N. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010, 65:ii4-ii17. 10.1136\/thx.2010.136978","journal-title":"Thorax"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0377","article-title":"Pleural effusion in adults \u2014\u00a0etiology, diagnosis, and treatment","volume":"116","author":"Jany B","year":"2019","unstructured":"Jany B, Welte T. Pleural effusion in adults \u2014\u00a0etiology, diagnosis, and treatment. Dtsch Arztebl Int. 2019, 116:377-386. 10.3238\/arztebl.2019.0377","journal-title":"Dtsch Arztebl Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.20108","article-title":"The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas","volume":"118","author":"Stoll LM","year":"2010","unstructured":"Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol. 2010, 118:441-449. 10.1002\/cncy.20108","journal-title":"Cancer Cytopathol"},{"key":"ref10","article-title":"Pulmonary Pathology (Article in Italian)","author":"Funkhouser WK","unstructured":"Funkhouser WK. Pulmonary Pathology (Article in Italian). Pathology \u2014 A Modern Case Study. Reisner HM (ed): McGraw-Hill Education,"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Castellar ERP","year":"2014","unstructured":"Castellar ERP, Jaffe ES, Said JW, et al.. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014, 124:1473-1480. 10.1182\/blood-2014-04-571091","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2019.12.002","article-title":"Pathology and genetics of anaplastic large cell lymphoma","volume":"37","author":"Leventaki V","year":"2020","unstructured":"Leventaki V, Bhattacharyya S, Lim MS. Pathology and genetics of anaplastic large cell lymphoma. Semin Diagn Pathol. 2020, 37:57-71. 10.1053\/j.semdp.2019.12.002","journal-title":"Semin Diagn Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/S00428-022-03412-6\/METRICS","article-title":"Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas","volume":"482","author":"Feldman AL","year":"2023","unstructured":"Feldman AL, Laurent C, Narbaitz M, Nakamura S, Chan WC, de Leval L, Gaulard P. Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas. Virchows Archiv. 2023, 482:265-279. 10.1007\/S00428-022-03412-6\/METRICS","journal-title":"Virchows Archiv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071650","article-title":"Anaplastic large cell lymphoma: molecular pathogenesis and treatment","volume":"14","author":"Zhang XR","year":"2022","unstructured":"Zhang XR, Chien PN, Nam SY, Heo CY. Anaplastic large cell lymphoma: molecular pathogenesis and treatment. Cancers (Basel). 2022, 14:10.3390\/cancers14071650","journal-title":"Cancers (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqab012","article-title":"How I diagnose anaplastic large cell lymphoma","volume":"155","author":"Amador C","year":"2021","unstructured":"Amador C, Feldman AL. How I diagnose anaplastic large cell lymphoma. Am J Clin Pathol. 2021, 155:479-497. 10.1093\/ajcp\/aqab012","journal-title":"Am J Clin Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmy035","article-title":"Anaplastic large cell lymphoma manifesting as pleural effusion in a patient with long-standing eosinophilia","volume":"50","author":"Belludi CK","year":"2019","unstructured":"Belludi CK, Qian ET, Tolle JJ, Brown RM, Thompson MA, Juskevicius R. Anaplastic large cell lymphoma manifesting as pleural effusion in a patient with long-standing eosinophilia. Lab Med. 2019, 50:87-92. 10.1093\/labmed\/lmy035","journal-title":"Lab Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2018-99-115620","article-title":"Comparison of prognostic stratification between IPI, PIT, and NCCN-IPI in the treatment of nodal peripheral T-cell lymphomas","volume":"132","author":"Yhim H-Y","year":"2018","unstructured":"Yhim H-Y, Park Y, Moon JH, et al.. Comparison of prognostic stratification between IPI, PIT, and NCCN-IPI in the treatment of nodal peripheral T-cell lymphomas. Blood. 2018, 132:1657. 10.1182\/BLOOD-2018-99-115620","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_6","article-title":"Anaplastic large cell lymphoma: contemporary concepts and optimal management","volume":"176","author":"Shustov A","year":"2019","unstructured":"Shustov A, Soma L. Anaplastic large cell lymphoma: contemporary concepts and optimal management. Cancer Treat Res. 2019, 176:127-144. 10.1007\/978-3-319-99716-2_6","journal-title":"Cancer Treat Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro B","year":"2017","unstructured":"Pro B, Advani R, Brice P, et al.. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017, 130:2709-2717. 10.1182\/blood-2017-05-780049","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/S12325-019-01046-W\/TABLES\/6","article-title":"Hematopoietic stem cell transplantation and brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma","volume":"36","author":"Ishizawa K","year":"2019","unstructured":"Ishizawa K, Yanai T. Hematopoietic stem cell transplantation and brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. Adv Ther. 2019, 36:2679-2696. 10.1007\/S12325-019-01046-W\/TABLES\/6","journal-title":"Adv Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1558399","article-title":"Brentuximab vedotin in T-cell lymphoma","volume":"12","author":"Van Der Weyden C","year":"2019","unstructured":"Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Brentuximab vedotin in T-cell lymphoma. Expert Rev Hematol. 2019, 12:5-19. 10.1080\/17474086.2019.1558399","journal-title":"Expert Rev Hematol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000101","article-title":"Strategies for aggressive T-cell lymphoma: divide and conquer","volume":"2020","author":"Pinter-Brown LC","year":"2020","unstructured":"Pinter-Brown LC. Strategies for aggressive T-cell lymphoma: divide and conquer. Hematology Am Soc Hematol Educ Program. 2020, 2020:154-159. 10.1182\/hematology.2020000101","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001821","article-title":"Brentuximab vedotin in the treatment of CD30+ PTCL","volume":"134","author":"Barta SK","year":"2019","unstructured":"Barta SK, Gong JZ, Porcu P. Brentuximab vedotin in the treatment of CD30+ PTCL. Blood. 2019, 134:2339-2345. 10.1182\/blood.2019001821","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz S","year":"2019","unstructured":"Horwitz S, O'Connor OA, Pro B, et al.. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019, 393:229-240. 10.1016\/S0140-6736(18)32984-2","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/228253-anaplastic-lymphoma-kinase-alk-negative-anaplastic-large-cell-non-hodgkin-lymphoma-as-a-rare-differential-diagnosis-of-lung-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T18:23:22Z","timestamp":1709231002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/228253-anaplastic-lymphoma-kinase-alk-negative-anaplastic-large-cell-non-hodgkin-lymphoma-as-a-rare-differential-diagnosis-of-lung-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.55258","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}